COMPANY
Rubicon Biotechnology
NIH awards 6
- NIH award 1R43EY028076-01A1 FY2017: $212,466 awarded for that fiscal year; activity R43 (SBIR); PI PARSEGHIAN, MISSAG HAGOP; recipient as written: RUBICON BIOTECHNOLOGY, INC., Irvine, CA. Targeted Hsp72 as a Therapeu source ↗
- NIH award 1R43CA192775-01A1 FY2015: $292,989 awarded for that fiscal year; activity R43 (SBIR); PI PARSEGHIAN, MISSAG HAGOP; recipient as written: RUBICON BIOTECHNOLOGY, INC., Irvine, CA. Modified Annexin V for immun source ↗
- NIH award 3R21ES024028-02S1 FY2014: $50,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI PARSEGHIAN, MISSAG HAGOP; recipient as written: RUBICON BIOTECHNOLOGY, INC., Irvine, CA. Intracellular targeting source ↗
- NIH award 5R21ES024028-02 FY2014: $300,186 awarded for that fiscal year; activity R21 (OTHER_NIH); PI PARSEGHIAN, MISSAG HAGOP; recipient as written: RUBICON BIOTECHNOLOGY, INC., Irvine, CA. Intracellular targeting H source ↗
- NIH award 1R43HL122012-01A1 FY2014: $223,333 awarded for that fiscal year; activity R43 (SBIR); PI PARSEGHIAN, MISSAG HAGOP; recipient as written: RUBICON BIOTECHNOLOGY, INC., Irvine, CA. Intracellular targeting Hsp7 source ↗
- NIH award 1R21ES024028-01 FY2013: $318,914 awarded for that fiscal year; activity R21 (OTHER_NIH); PI PARSEGHIAN, MISSAG HAGOP; recipient as written: RUBICON BIOTECHNOLOGY, INC., Irvine, CA. Intracellular targeting H source ↗